Home › Parkinson's Disease › NCT06772220

Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease

Who can join

Ages 40 to 90 · All sexes

Inclusion Criteria:

1. Diagnosis of probable Parkinson's Disease according to Movement Disorders Society criteria.
2. Currently treated with levodopa at a minimum dose of 300 mg/day
3. Montreal Cognitive Assessment (MOCA) ≥15
4. Demonstrated capacity to provide informed consent.
5. 40-90 years of age
6. Estimated glomerular filtration rate ≥60
7. Absence of uncontrolled hypertension in medical history
8. Absence of insulin use

Exclusion Criteria:

\-

About the study

This is a research study investigating elevated homocysteine in the blood of patients with Parkinson's disease who are currently receiving treatment with levodopa. We are evaluating if elevated homocysteine can be corrected using open label B vitamin therapy, as well as the impact of homocysteine levels on cognitive function.

What is being tested

• Folic Acid 1 MG (dietary supplement)
• Vitamin B6 25 MG (dietary supplement)
• Vitamin B12 (dietary supplement)

Sponsor: Oregon Health and Science University · Participants: 150 · Started: Mar 5, 2024

Contact the study team

• Madeline Armendariz Sullivan · Phone: 503-501-8478

Official record on ClinicalTrials.gov — NCT06772220

Locations in the U.S.

Conditions

• Parkinson's Disease

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.